KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Kyverna Therapeutics, Inc. due to a class action complaint alleging that the company made false and misleading statements regarding its IPO and ongoing trials [1][2] Summary by Sections Investigation Details - The investigation focuses on whether Kyverna's board of directors breached their fiduciary duties, particularly in light of undisclosed adverse data related to one of its lead products [1][2] - The complaint asserts that Kyverna's public statements were materially misleading, as they failed to adequately disclose risks associated with withholding clinical data [2] Class Action Context - The class action complaint was filed on December 9, 2024, concerning the company's IPO conducted on February 8, 2024 [1] - Investors reportedly suffered damages when the truth about Kyverna's situation became known to the market [2] Next Steps for Investors - Long-term stockholders of Kyverna are encouraged to reach out for more information regarding the claims and their rights [3]